Brief: US FDA And CEL-SCI Agree On Use Of PD-L1 Biomarker

CEL-SCI

07/11/2024 13:18

Nov 7 (Reuters) - CEL-SCI Corp  CVM.A :
    * U.S. FDA AND CEL-SCI AGREE ON USE OF PD-L1 BIOMARKER TO
SELECT
HEAD AND NECK CANCER PATIENTS FOR MARKETING REGISTRATION STUDY
TO COMMENCE Q1 2025

Source text:  ID:nBw4lGrkma 
Further company coverage:  CVM.A 

 (Reuters.Briefs@thomsonreuters.com)